Study finds reduced risk of graft-versus-host disease with low-dose steroids | Portugal reports results for new hepatitis C treatments | Brazil reports over 91,000 suspected cases of Zika infection
April 28, 2016
AABB SmartBrief
News for the transfusion medicine and cellular therapy community
Top Story
Study finds reduced risk of graft-versus-host disease with low-dose steroids
Researchers in Beijing found that haploidentical stem cell transplant recipients who received low-dose corticosteroid prophylaxis had lower rates of grades II to IV acute graft-versus-host disease, according to a study in the Journal of Clinical Oncology. The randomized trial, which involved 228 patients, also found that low-dose steroid therapy was associated with faster platelet recovery and a low rate of adverse events.
MedPage Today (free registration) (4/26) 
LinkedIn Twitter Facebook Google+ Email
Fresenius Kabi. Your source for Fenwal products.
Putting lifesaving medicines and technologies in your hands. Finding answers to the challenges you face. That's been the purpose of Fresenius Kabi for decades. And with the Fenwal family of transfusion products in our portfolio, you now have a partner with even more resources, experience, and caring. Click here to learn more.
Science & Health
Portugal reports results for new hepatitis C treatments
A February 2015 Portuguese health policy granted comprehensive access to direct acting antivirals for patients with hepatitis C. Based on an analysis of data for 1,069 people who had been assessed following treatment by the end of January, 94% achieved a sustained virological response. The data were presented at the International Liver Congress.
Aidsmap (4/27) 
LinkedIn Twitter Facebook Google+ Email
Brazil reports over 91,000 suspected cases of Zika infection
Health officials in Brazil announced that 91,387 cases of Zika virus infection were reported from Jan. 3 to April 2, with a high share in the nation's Northeast. The Health Ministry also said dengue cases rose by 13.7% compared with the same period the previous year.
Yahoo/Agence France-Presse (4/27) 
LinkedIn Twitter Facebook Google+ Email
Emerging Trends
Modified antibodies show potential against HIV in animal trials
Investigators with the National Institute of Allergy and Infectious Diseases found that four antibodies were capable of protecting macaque monkeys from a combination of HIV and a simian form of the virus, according to a study in the journal Nature. A genetically modified version of VRC01 protected the primates longer than the original antibody.
HealthDay News (4/27) 
LinkedIn Twitter Facebook Google+ Email
Industry News & Practice
GlaxoSmithKline to collaborate with Zymeworks on antibody development
GlaxoSmithKline will work with Zymeworks on the development and marketing of bispecific antibodies using the latter's Azymetric drug discovery technology. Under the terms of the agreement, GSK gets the option to develop and market the antibodies for multiple indications and will provide Zymeworks with an upfront payment of $36 million and as much as $872 million in milestone fees plus sales royalties.
Genetic Engineering & Biotechnology News (4/26) 
LinkedIn Twitter Facebook Google+ Email
IPO could bring in $85M for Intellia Therapeutics
Intellia Therapeutics has filed updated plans for an initial public offering with the goal of raising $85 million. The Cambridge, Mass.-based firm uses CRISPR-Cas9 technology for the development of gene-editing treatments.
GenomeWeb Daily News (free registration) (4/27),  Renaissance Capital (4/27) 
LinkedIn Twitter Facebook Google+ Email
Q2 revenue increases for Hologic
Hologic generated $693.3 million in revenue during its fiscal second quarter ending March 26, up from $655.5 million in the same period a year earlier. The growth was driven in part by a 14% year-over-year increase in US gynecology surgical business sales, which was the company's biggest overall gain.
GenomeWeb Daily News (free registration) (4/27) 
LinkedIn Twitter Facebook Google+ Email
Getting Ready for Patient Blood Management Certification Webinar
Join experts from The Joint Commission and AABB for a FREE webinar, Getting Ready for Patient Blood Management Certification, May 12 at 2:00 ET. Attendees will learn more about the benefits of the new Patient Blood Management Certification Program and how to prepare for and build support within your organization. Joint Commission accredited hospitals and critical access hospitals are eligible for the new voluntary certification. Register now.
Association News
Reminder: Annual Meeting abstract submission deadline is May 4
The deadline to submit abstracts is May 4 for the 2016 AABB Annual Meeting, taking place Oct. 22-25 in Orlando, Fla. This year, AABB will accept 20 percent more abstracts for oral presentations and present $500 awards to 2 trainees in each of the 5 categories who submit outstanding abstracts -- submit yours today.
LinkedIn Twitter Facebook Google+ Email
Learn more about AABB®:
Homepage | Join AABB | Conferences
Marketplace | AABB CareerLink
powered by
Donor Services Supervisor
If you are not willing to risk the unusual, you will have to settle for the ordinary.
Jim Rohn,
entrepreneur and motivational speaker
LinkedIn Twitter Facebook Google+ Email
Sign Up
SmartBrief offers 200+ newsletters
Subscriber Tools:
Contact Us:
Advertising  -  Meryl Harold
P: 202.407.7828
Editor  -  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2016 SmartBrief, Inc.®
Privacy policy |  Legal Information